证券代码：603259 证券简称：药明康德 公告编号：临 2025-026 无锡药明康德新药开发股份有限公司 关于回购注销部分股票通知债权人的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 6 月 12 日，无锡药明康德新药开发股份有限公司（以下简称"本公 司"或"公司"）召开 2023 年年度股东大会、2024 年第二次 A 股类别股东会议 和 2024 年第二次 H 股类别股东会议，审议通过了《关于给予董事会回购公司 A 股和/或 H 股股份一般性授权的议案》，授权董事会按照所适用的法律法规和/或 规定行使公司全部权力，在有关期间回购公司 A 股和/或 H 股总面值不超过该议 案经股东大会、A 股及 H 股类别股东会议分别审议通过之日公司已发行 A 股和/ 或 H 股股份数量的 10%。具体内容详见 2024 年 6 月 13 日公司于上海证券交易 所网站及指定媒体披露的《2023 年年度股东大会、2024 年第二次 A 股类别股东 会议及 2024 年第二次 H 股类别股东会议决议公告》（公告编号：20 ...

智通财经4月8日电，药明康德(603259.SH)公告称，公司董事会同意继续通过集中竞价交易方式回购公 司A股股份，回购金额为10亿元，所回购的股份将全部注销并减少注册资本。 药明康德：拟以10亿元回购A股股份并注销 ...

Group 1 - The core index, the China Securities Chuangxin Quality Growth Index, rose by 0.92% to 6368.71 points, with a trading volume of 370.183 billion yuan [1] - Over the past month, the index has decreased by 8.87%, by 3.80% over the last three months, and by 7.25% year-to-date [1] - The index selects listed companies with high return on equity across various industries, providing diverse investment options for investors [1] Group 2 - The top ten weighted stocks in the index include Kweichow Moutai (9.8%), BYD (2.99%), Wuliangye (2.56%), Dongfang Fortune (2.51%), and others [1] - The index's holdings are primarily from the Shanghai Stock Exchange (53.96%) and Shenzhen Stock Exchange (46.04%) [1] - The industry composition of the index shows that consumer staples account for 20.20%, industrials for 17.60%, and financials for 10.81%, among others [2] Group 3 - The index samples are adjusted four times a year, specifically in March, May, September, and November on the next trading day after the second Friday [2] - Weight factors are adjusted in accordance with the sample adjustments, which are generally fixed until the next scheduled adjustment [2] - Special circumstances may lead to temporary adjustments of the index, including the removal of samples that are delisted or undergo mergers and acquisitions [2]

Group 1 - The CRO (Contract Research Organization) sector experienced a significant downturn, with WuXi AppTec hitting the daily limit down [1] - Other companies in the sector, such as Kelun Pharmaceutical, also approached the daily limit down, indicating a widespread decline [1] - Additional firms like Boteng, Meinohua, Zhaoyan New Drug, Jiuzhou Pharmaceutical, and Baihua Medicine followed suit with declines [1]

Core Viewpoint - WuXi AppTec's stock experienced a significant decline of 10.0% on April 7, indicating potential concerns among investors regarding the company's performance and market position [1]. Company Overview - WuXi AppTec, established in 2000, is located in Wuxi and primarily engages in research and development activities. The company has a registered capital of 29.53 billion RMB, with GE LI serving as the legal representative [1]. Shareholder Activity - Among WuXi AppTec's top shareholders is the China Europe Fund, which reduced its holdings in the company during the fourth quarter of the previous year. The fund has reported a year-to-date return of 4.45%, ranking 1657 out of 4592 in its category [1]. Fund Management - The fund manager of the China Europe Healthcare Mixed Fund is Ms. Ge Lan, who has a background in biomedical engineering from Northwestern University. She has held various research and fund management positions since joining China Europe Fund Management in October 2014 [4][5].

Core Viewpoint - WuXi AppTec (603259.SH, 02359.HK) announced a block trade to reduce its stake in WuXi Biologics (02268.HK) by 50.8 million shares, accounting for approximately 4.23% of WuXi Biologics' total share capital, with a transaction value of about HKD 2.178 billion [1][3]. Group 1: Share Reduction and Financial Impact - This marks the third reduction by WuXi AppTec since November 2024, with a cumulative reduction amounting to HKD 4.6 billion [3]. - The recent share reduction occurred when WuXi Biologics' stock price reached an all-time high [3]. - The investment gain from this reduction is approximately RMB 1.847 billion, representing over 10% of the projected net profit for 2024 [5]. Group 2: Strategic Response to Market Conditions - The global pharmaceutical outsourcing industry is facing intensified competition, with WuXi AppTec encountering multiple challenges from geopolitical and trade policies [5]. - Approximately 64% of WuXi AppTec's revenue is derived from the U.S. market, making it vulnerable to the impending "reciprocal tariff" policy, which could significantly impact its profitability [5]. - In response, WuXi AppTec is accelerating its global expansion, including the construction of a new facility in Middleton, USA, expected to be operational by the end of 2026 [5][6]. Group 3: Future Growth and Talent Acquisition - The funds raised from the share reduction will be primarily allocated to accelerate global capacity building, attract and retain top talent, and enhance its integrated CRDMO business model [5][6]. - WuXi Biologics, as the second-largest ADC CRDMO company globally, reported impressive performance in 2024, with revenues of RMB 4.052 billion, a year-on-year increase of 90.8%, and a net profit growth of 277.2% [6]. - The independent operation of WuXi Biologics allows it to focus on high-value areas such as ADC research and production, while WuXi AppTec can concentrate more resources on its core business, strengthening its leading position in the global pharmaceutical outsourcing market [6][7].

環境、社會及管治報告 2024 目錄 | 關於本報告 | 03 | | --- | --- | | 董事長兼首席執行官致辭 | 04 | | 2024 ESG 亮點績效 | 05 | | 2024 ESG 評級表現 | 06 | | 關於藥明康德 | | 賦能客戶 | | | --- | --- | --- | --- | | 我們的管治 | 09 | 產品與服務質量 | 38 | | | | 可持續供應鏈 | 42 | | ESG 管理策略 | | 守護地球 | | | ESG 治理 | 16 | 氣候變化 | 48 | | ESG 管理 | 18 | 排放管理 | 58 | | 重要性議題評估 | 20 | 資源管理 | 62 | | 責任公民 | | 社區共建 | | | 商業道德與合規 | 25 | 我們的員工 | 67 | | 反腐敗與反賄賂 | 29 | 我們的工作環境 | 73 | | 信息安全保護 | 32 | 我們的社區 | 76 | 79 86 績效表 附錄 關於藥明康德 ESG 管理策略 責任公民 賦能客戶 守護地球 社區共建 績效表 03 關於本報告 報告範圍及邊界 本報告中提供的政策 ...

2024 环境、社会及管治报告 目录 | 关于本报告 | 03 | | --- | --- | | 董事长兼首席执行官致辞 | 04 | | 2024 ESG 亮点绩效 | 05 | | 2024 ESG 评级表现 | 06 | | 关于药明康德 | | 赋能客户 | | --- | --- | --- | | 我们的管治 | 09 | 产品与服务质量 | | | | 可持续供应链 | | ESG 管理策略 | | 守护地球 | | ESG 治理 | 16 | 气候变化 | | ESG 管理 | 18 | 排放管理 | | 重要性议题评估 | 20 | 资源管理 | | 责任公民 | | 社区共建 | | 商业道德与合规 | 25 | 我们的员工 | | 反腐败与反贿赂 | 29 | 我们的工作环境 | | 信息安全保护 | 32 | 我们的社区 | | 38 | | --- | | 42 | | 48 | | --- | | 58 | | 62 | | 67 | | --- | | 73 | | 76 | 79 86 绩效表 附录 关于药明康德 ESG 管理策略 责任公民 赋能客户 守护地球 社区共建 绩效 ...

Financial Performance - In 2024, the company's revenue reached RMB 39,241.4 million, a decrease of 2.7% compared to RMB 40,340.8 million in 2023[12] - The net profit attributable to the parent company was RMB 9,352.6 million, down 12.5% from RMB 10,690.2 million in the previous year[12] - The company achieved operating revenue of RMB 39,241.4 million, a decrease of 2.7% year-on-year, with net profit attributable to shareholders at RMB 9,352.6 million, down 12.5%[14] - The adjusted net profit attributable to the parent company for the year ended December 31, 2024, was RMB 10,582.5 million, slightly down from RMB 10,854.6 million in 2023, with an adjusted gross profit of RMB 16,326.3 million, down from RMB 16,937.8 million, resulting in an adjusted gross margin of 41.6%[39] - The gross profit for 2023 was RMB 16,372,472 thousand, with a gross margin of 40.6%, up from 36.9% in 2022[97] Assets and Liabilities - The total assets increased to RMB 80,325.8 million, up from RMB 73,669.3 million in 2023, reflecting a growth of 9.0%[13] - The total liabilities increased to RMB 21,240.2 million, up from RMB 18,151.9 million in 2023[13] - Total liabilities rose to RMB 21,240.2 million as of December 31, 2024, from RMB 18,151.9 million in 2023, with a debt-to-asset ratio of 26.4%[33] - The company reported a decrease in goodwill to RMB 972.4 million as of December 31, 2024, down 46.6% from RMB 1,820.9 million in 2023, primarily due to reclassification to assets held for sale[40] Cash Flow and Financial Position - The company reported a cash and cash equivalents balance of RMB 13,434.3 million, significantly higher than RMB 10,001.0 million in the previous year[13] - Cash generated from operating activities was RMB 11,986.8 million, a decrease of 5.2% year-on-year, but excluding COVID-19 commercialization projects, it increased by RMB 2,100 million, or 22.1%[31] - The company reported a free cash flow of RMB 7,983.3 million for the year ended December 31, 2024, compared to RMB 7,124.7 million in 2023[31] - The company experienced a significant increase in tax receivables, which rose to RMB 87.2 million as of December 31, 2024, compared to RMB 17.5 million in 2023, marking a 397.4% increase[40] Business Growth and Market Position - The company achieved a record high of RMB 49.31 billion in backlog orders, representing a 47.0% year-on-year increase[9] - The company expects a revenue growth of 10-15% for its continuing operations in 2025[9] - The company anticipates a return to double-digit growth in continuing operations revenue in 2025, projecting a year-on-year increase of 10% to 15%[19] - Revenue from the top 20 global pharmaceutical companies reached RMB 16.64 billion, with a year-on-year growth of 24.1% excluding COVID-19 commercialization projects[14] - The chemical business generated revenue of RMB 29,052.4 million, with a year-on-year growth of 11.2% when excluding COVID-19 projects[16] Operational Efficiency and Strategic Initiatives - The company aims to enhance operational efficiency and expand globally to meet increasing customer innovation demands[9] - The company plans to enhance its production capacity, with the total volume of small molecule API reactors expected to exceed 4,000 kL by the end of 2025[58] - The company has doubled its oral formulation capacity at its Swiss facility during 2024[58] - The company is expanding its capabilities in various innovative technologies, including continuous flow purification and new drug formulation techniques[54] - The company aims to strengthen its global capabilities and scale to better empower pharmaceutical innovation[54] Governance and Management - The board consists of 12 members, including 5 executive directors, 2 non-executive directors, and 5 independent non-executive directors[101] - The company has a strong governance structure with a diverse board of directors and experienced management team, ensuring effective oversight and strategic direction[132] - The company has established a comprehensive internal control system to ensure compliance with laws and regulations, although risks remain due to the number of subsidiaries[88] - The company is committed to ensuring that the compensation for non-independent directors and senior management aligns with contractual terms and is fair and reasonable[181] - The company has received annual written confirmations of independence from all independent non-executive directors, affirming their status as independent individuals[150] Risks and Challenges - The company faces risks from potential declines in demand for pharmaceutical R&D services due to market trends or budget adjustments by clients[85] - Regulatory changes in the pharmaceutical R&D services industry may pose risks if the company cannot adapt its strategies accordingly[86] - The company faces intensified competition in the pharmaceutical R&D services market, particularly from large international pharmaceutical companies and new market entrants[87] Shareholder Returns and Incentives - A cash dividend of RMB 9.8974 per 10 shares was approved for distribution to shareholders listed on the register as of June 25, 2024[65] - The company decided to terminate the 2023 H-share incentive trust plan and plans to repurchase and cancel 15,467,500 H-shares[67] - The 2024 H-share incentive trust plan was approved, with a total of HKD 1 billion used to purchase 27,478,428 H-shares, accounting for approximately 0.94% of the total issued share capital[68]

Core Viewpoint - WuXi AppTec has sold 50.8 million shares of its associate WuXi Biologics through block trading, raising approximately HKD 21.78 billion, which is expected to significantly enhance its financial performance in 2025 [1][2]. Group 1: Share Sale Details - The share sale represents 4.23% of WuXi Biologics' total share capital and is part of a series of three sales within six months, totaling a 11.4% reduction in holdings and over HKD 46 billion raised [1]. - WuXi AppTec's subsidiary, WuXi Biologics, remains the second-largest shareholder with a 33.94% stake after the sale [1]. Group 2: Financial Performance - WuXi Biologics reported a revenue of RMB 4.052 billion for 2024, a year-on-year increase of 90.77%, and a net profit of RMB 1.07 billion, up 276.76% [2]. - In contrast, WuXi AppTec's revenue for 2024 was RMB 39.241 billion, a decline of 2.73%, with a net profit of RMB 9.450 billion, down 1.63%, marking the first decline in recent years [2]. Group 3: Strategic Initiatives - The funds from the share sale will be used to accelerate global capacity and capability building, as well as to attract and retain key talent [2]. - WuXi AppTec is expanding its global production capacity, with new facilities in Taixing and Switzerland, and plans for a Singapore R&D and production base to be operational by 2027 [2]. Group 4: Geopolitical Risks - WuXi AppTec faces geopolitical risks, particularly from uncertainties in the U.S. market, where 64% of its revenue (approximately RMB 25.02 billion) is derived [3]. - To mitigate potential risks from U.S. tariffs, the company is accelerating the construction of its Middleton facility, expected to be operational by the end of 2026 [3].